Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Roivant Sciences Ltd. or AbCellera Biologics Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Roivant Sciences Ltd. and AbCellera Biologics Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Roivant Sciences Ltd. and AbCellera Biologics Inc.

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Latest Biotechnology and Roivant Sciences Ltd., AbCellera Biologics Inc. Stock News

As of July 31, 2026, Roivant Sciences Ltd. had a $24.4 billion market capitalization, compared to the Biotechnology median of $252.6 million. Roivant Sciences Ltd.’s stock is up 56.3% in 2026, down 3.1% in the previous five trading days and up 197.46% in the past year.

Currently, Roivant Sciences Ltd. does not have a price-earnings ratio. Roivant Sciences Ltd.’s trailing 12-month revenue is $8.3 million with a % net profit margin. Year-over-year quarterly sales growth most recently was -67.1%. Analysts expect adjusted earnings to reach $-1.496 per share for the current fiscal year. Roivant Sciences Ltd. does not currently pay a dividend.

As of July 31, 2026, AbCellera Biologics Inc. had a $1.7 billion market cap, putting it in the 52nd percentile of all stocks. AbCellera Biologics Inc.’s stock is up 67% in 2026, up 7.5% in the previous five trading days and up 24.95% in the past year.

Currently, AbCellera Biologics Inc. does not have a price-earnings ratio. AbCellera Biologics Inc.’s trailing 12-month revenue is $79.2 million with a -181.7% net profit margin. Year-over-year quarterly sales growth most recently was 97.6%. Analysts expect adjusted earnings to reach $-0.650 per share for the current fiscal year. AbCellera Biologics Inc. does not currently pay a dividend.

How We Compare Roivant Sciences Ltd. and AbCellera Biologics Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Roivant Sciences Ltd. and AbCellera Biologics Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Roivant Sciences Ltd. and AbCellera Biologics Inc.’s Quality Grades

Company	Ticker	Quality
Roivant Sciences Ltd.	ROIV	D
AbCellera Biologics Inc.	ABCL	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Roivant Sciences Ltd. has a Quality Score of 25, which is Weak. AbCellera Biologics Inc. has a Quality Score of 21, which is Weak.

The Quality Stock Winner: No Clear Winner

Neither Roivant Sciences Ltd. or AbCellera Biologics Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Roivant Sciences Ltd. or AbCellera Biologics Inc. is the better investment when it comes to quality.

Roivant Sciences Ltd. and AbCellera Biologics Inc.’s Momentum Grades

Company	Ticker	Momentum
Roivant Sciences Ltd.	ROIV	A
AbCellera Biologics Inc.	ABCL	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Roivant Sciences Ltd. has a Momentum Score of 95, which is Very Strong. AbCellera Biologics Inc. has a Momentum Score of 81, which is Very Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Roivant Sciences Ltd. and AbCellera Biologics Inc. have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Roivant Sciences Ltd. and AbCellera Biologics Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Roivant Sciences Ltd.	ROIV	D
AbCellera Biologics Inc.	ABCL	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Roivant Sciences Ltd. has a Earnings Estimate Score of 30, which is Negative. AbCellera Biologics Inc. has a Earnings Estimate Score of 67, which is Positive.

The Earnings Estimate Revisions Grade Winner: AbCellera Biologics Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, AbCellera Biologics Inc. has a better Earnings Estimate Revisions Grade than Roivant Sciences Ltd.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, AbCellera Biologics Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Roivant Sciences Ltd. and AbCellera Biologics Inc. Grades

In addition to Momentum, Quality and Estimate Revisions, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Roivant Sciences Ltd. and AbCellera Biologics Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Roivant Sciences Ltd. or AbCellera Biologics Inc. Stock?

Overall, Roivant Sciences Ltd. stock has a Momentum Score of 95, Estimate Revisions Score of 30 and Quality Score of 25.

AbCellera Biologics Inc. stock has a Momentum Score of 81, Estimate Revisions Score of 67 and Quality Score of 21.

Comparing Roivant Sciences Ltd. and AbCellera Biologics Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.